Hedge funds have stepped up bets on U.S. healthcare stocks, pushing relative exposure to a level that Goldman Sachs said last week was near a five-year high. The bank's note, dated July 24, said this was the second consecutive week in which these funds increased their allocations to the sector versus U.S. equities as a whole.
The move comes amid a year-to-date advance in healthcare benchmarks. The S&P 500 healthcare index has risen almost 5% so far this year, while related European healthcare stocks have climbed around 2% during the same period, according to the figures cited by Goldman Sachs.
Goldman Sachs' research identified a clear pattern in the flows: hedge funds were buying shares in healthcare equipment and supplies, life sciences tools, and pharmaceutical companies. Those sector-level purchases, the bank's note said, reflect concentrated bets that advances and financing conditions will reward these positions.
The bank pointed to several catalysts that are supporting momentum in the space. One prominent theme is the use of artificial intelligence in drug discovery. Goldman Sachs' earlier report highlighted rising research productivity tied to AI and an expectation that deal activity that could help certain stock positions would reach $173 billion in 2026 - a level it said would be the highest since 2019.
Regulatory timing was another factor cited by Goldman Sachs. The Food and Drug Administration has, the note said, expedited its approval process, with last year’s annual tally of new drug approvals reaching its highest level since 2020, referencing data through the end of 2025. At the same time, some market participants have noted greater variability in regulatory outcomes.
"Volatility in the regulatory process of getting a drug approved has increased this year," said Felix Lo, a hedge fund portfolio manager at Trium Capital, summarizing the current environment. Lo also observed a deal-related dynamic in which smaller pharmaceutical companies being acquired are often willing to accept larger discounts in exchange for the certainty of cash, a trend he said has "created a robust environment for deals."
Performance trends have reinforced investor interest in specialized approaches to healthcare. Goldman Sachs' healthcare-focused report said specialised healthcare hedge funds returned near 40% between August 2025 and April 2026, compared with returns of 17% for generalist stock-trading hedge funds over the same period.
The bank also reported a rise in the number of funds concentrating exclusively on healthcare. It said 24% of this year's new hedge fund launches were dedicated to the sector - the highest share since at least 2009.
In terms of assets under management, Goldman Sachs estimated that of roughly $1 trillion managed by equity hedge funds, approximately $283 billion is managed by firms specialising in healthcare. Industry-wide capital in hedge funds also swelled in the second quarter, with hedge fund research firm HFR reporting a record increase of $409.3 billion, bringing total industry capital to $5.6 trillion, the data said on Friday.
Implications
Heightened allocations to healthcare from hedge funds underscore how funding conditions, technological optimism and regulatory developments can converge to reshape sector-level investor appetite. The flow into equipment, life sciences tools and pharmaceuticals suggests a targeted thesis that spans medtech, biotech and drugmakers.